WO2005103037A3 - Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments - Google Patents

Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2005103037A3
WO2005103037A3 PCT/EP2005/004104 EP2005004104W WO2005103037A3 WO 2005103037 A3 WO2005103037 A3 WO 2005103037A3 EP 2005004104 W EP2005004104 W EP 2005004104W WO 2005103037 A3 WO2005103037 A3 WO 2005103037A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
methods
medicaments
cgrp antagonists
salts
Prior art date
Application number
PCT/EP2005/004104
Other languages
German (de)
English (en)
Other versions
WO2005103037A2 (fr
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Gerhard Schaenzle
Kirsten Arndt
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Gerhard Schaenzle
Kirsten Arndt
Henri Doods
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Stephan Georg Mueller, Klaus Rudolf, Philipp Lustenberger, Dirk Stenkamp, Marco Santagostino, Fabio Paleari, Gerhard Schaenzle, Kirsten Arndt, Henri Doods filed Critical Boehringer Ingelheim Int
Priority to EP05735460A priority Critical patent/EP1740577A2/fr
Priority to CA002565219A priority patent/CA2565219A1/fr
Priority to JP2007508815A priority patent/JP2007533689A/ja
Publication of WO2005103037A2 publication Critical patent/WO2005103037A2/fr
Publication of WO2005103037A3 publication Critical patent/WO2005103037A3/fr
Priority to KR1020077024324A priority patent/KR20070114831A/ko
Priority to MX2007011527A priority patent/MX2007011527A/es
Priority to BRPI0607577-0A priority patent/BRPI0607577A2/pt
Priority to EP06723538A priority patent/EP1863799A1/fr
Priority to PCT/EP2006/002515 priority patent/WO2006100009A1/fr
Priority to CA002600909A priority patent/CA2600909A1/fr
Priority to JP2008502299A priority patent/JP2008538209A/ja
Priority to RU2007138881/04A priority patent/RU2007138881A/ru
Priority to AU2006226615A priority patent/AU2006226615A1/en
Priority to TW095109753A priority patent/TW200700408A/zh
Priority to US11/277,177 priority patent/US7528129B2/en
Priority to IL186090A priority patent/IL186090A0/en
Priority to US12/707,890 priority patent/US20100144716A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne les antagonistes du CGRP représentés par la formule générale (I), dans laquelle A, X, Q et R1 à R3 sont tels que définis dans la revendication n°1, ainsi que leurs tautomères, isomères, diastéréoisomères, énantiomères, hydrates, mélanges et sels et les hydrates de ces sels, notamment leurs sels physiologiquement tolérables contenant des acides inorganiques ou organiques. L'invention concerne également des médicaments contenant ces composés, leur utilisation et des procédés de production desdits composés.
PCT/EP2005/004104 2004-04-22 2005-04-18 Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments WO2005103037A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP05735460A EP1740577A2 (fr) 2004-04-22 2005-04-18 Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
CA002565219A CA2565219A1 (fr) 2004-04-22 2005-04-18 Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
JP2007508815A JP2007533689A (ja) 2004-04-22 2005-04-18 選択されたｃｇｒｐアンタゴニスト、その製造方法及びその薬物としての使用
AU2006226615A AU2006226615A1 (en) 2005-03-23 2006-03-18 CGRP antagonists, method for the production thereof, and their use as medicaments
RU2007138881/04A RU2007138881A (ru) 2005-03-23 2006-03-18 Антагонисты cgrp-пептида, способ их получения, а также их применение в качестве лекарственных средств
BRPI0607577-0A BRPI0607577A2 (pt) 2005-03-23 2006-03-18 antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
MX2007011527A MX2007011527A (es) 2005-03-23 2006-03-18 Nuevos antagonistas de cgrp, procedimiento para su preparacion, asi como su uso como medicamentos.
KR1020077024324A KR20070114831A (ko) 2005-03-23 2006-03-18 Ｃｇｒｐ 길항제, 이의 제조 방법 및 약제로서의 이의 용도
EP06723538A EP1863799A1 (fr) 2005-03-23 2006-03-18 Antagonistes cgrp, leur procédé de préparation ansi que leur utilisation comme médicaments
PCT/EP2006/002515 WO2006100009A1 (fr) 2005-03-23 2006-03-18 Antagonistes cgrp, procede de production associe et leur utilisation en tant que medicaments
CA002600909A CA2600909A1 (fr) 2005-03-23 2006-03-18 Antagonistes cgrp, procede de production associe et leur utilisation en tant que medicaments
JP2008502299A JP2008538209A (ja) 2005-03-23 2006-03-18 Ｃｇｒｐアンタゴニスト、それらの製造方法及び薬物としてのそれらの使用
TW095109753A TW200700408A (en) 2005-03-23 2006-03-22 New cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions
US11/277,177 US7528129B2 (en) 2005-03-23 2006-03-22 CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
IL186090A IL186090A0 (en) 2005-03-23 2007-09-20 Cgrp antagonists, method for the production thereof, and their use as medicaments
US12/707,890 US20100144716A1 (en) 2005-03-23 2010-02-18 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019492A DE102004019492A1 (de) 2004-04-22 2004-04-22 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492.0 2004-04-22

Publications (2)

Publication Number Publication Date
WO2005103037A2 WO2005103037A2 (fr) 2005-11-03
WO2005103037A3 true WO2005103037A3 (fr) 2006-01-12

Family

ID=35140095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004104 WO2005103037A2 (fr) 2004-04-22 2005-04-18 Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments

Country Status (9)

Country Link
EP (1) EP1740577A2 (fr)
JP (1) JP2007533689A (fr)
AR (1) AR049422A1 (fr)
CA (1) CA2565219A1 (fr)
DE (1) DE102004019492A1 (fr)
PE (1) PE20060186A1 (fr)
TW (1) TW200606151A (fr)
UY (1) UY28859A1 (fr)
WO (1) WO2005103037A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (fr) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN101500653A (zh) * 2006-06-08 2009-08-05 贝林格尔.英格海姆国际有限公司 使用cgrp拮抗剂对胃肠道病症的治疗
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
AU2008313733A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh CGRP antagonists
CA2705405A1 (fr) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Nouveaux composes
US9062046B2 (en) * 2010-07-16 2015-06-23 Piramal Enterprises Limited Substituted imidazoquinoline derivatives as kinase inhibitors
MX2016004250A (es) 2013-10-07 2016-07-12 Bayer Pharma AG Tienouracilcarboxamidas ciclicas y usos de las mismas.
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
JP6695441B2 (ja) 2016-03-03 2020-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−シアノ−ベンジルカルバミミドイルカルバメート誘導体およびａｏｃ３阻害剤としてのそれらの使用
WO2017148519A1 (fr) 2016-03-03 2017-09-08 Boehringer Ingelheim International Gmbh Dérivés pyridinylméthyl carbamimidoylcarbamate et leur utilisation comme inhibiteurs d'aoc3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018764A1 (fr) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Piperidines de benzimidazolinyle en tant que ligands de cgrp
WO2001010425A2 (fr) * 1999-08-10 2001-02-15 Boehringer Ingelheim Pharma Kg Utilisation d'antagonistes de cgrp et d'inhibiteurs de secretion cgrp servant a lutter contre les bouffees de chaleur de la menopause
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2004063171A1 (fr) * 2003-01-14 2004-07-29 Boehringer Ingelheim International Gmbh Derives de n- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyle) -1-piperidine-carboxamide et composes apparentes utilises comme antagonistes de cgrp et destines au traitement des maux de tete
WO2005095383A1 (fr) * 2004-03-29 2005-10-13 Bristol-Myers Squibb Company Emploi d'antagonistes heterocycliques de cgrp pour le traitement de la migraine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2000018764A1 (fr) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Piperidines de benzimidazolinyle en tant que ligands de cgrp
WO2001010425A2 (fr) * 1999-08-10 2001-02-15 Boehringer Ingelheim Pharma Kg Utilisation d'antagonistes de cgrp et d'inhibiteurs de secretion cgrp servant a lutter contre les bouffees de chaleur de la menopause
WO2004063171A1 (fr) * 2003-01-14 2004-07-29 Boehringer Ingelheim International Gmbh Derives de n- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyle) -1-piperidine-carboxamide et composes apparentes utilises comme antagonistes de cgrp et destines au traitement des maux de tete
WO2005095383A1 (fr) * 2004-03-29 2005-10-13 Bristol-Myers Squibb Company Emploi d'antagonistes heterocycliques de cgrp pour le traitement de la migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASTERNAK A ET AL: "Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 3, 8 February 1999 (1999-02-08), pages 491 - 496, XP004157253, ISSN: 0960-894X *
See also references of EP1740577A2 *

Also Published As

Publication number Publication date
EP1740577A2 (fr) 2007-01-10
TW200606151A (en) 2006-02-16
CA2565219A1 (fr) 2005-11-03
DE102004019492A1 (de) 2005-11-10
WO2005103037A2 (fr) 2005-11-03
UY28859A1 (es) 2005-11-30
PE20060186A1 (es) 2006-04-18
AR049422A1 (es) 2006-08-02
JP2007533689A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2005103037A3 (fr) Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
WO2004037811A8 (fr) Antagonistes du cgrp selectionnes, procedes de production et d'utilisation comme medicaments desdits antagonistes
WO2009065919A3 (fr) Nouveaux composés
WO2009065920A3 (fr) Nouveaux composés
UA88163C2 (ru) Cgrp-антагонисты, способ их получения, а также их применение как лекарственных средств
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2007036532A3 (fr) Antagonistes de cgrp selectionnes, procede pour les preparer et leur utilisation comme agents pharmaceutiques
WO2009065922A3 (fr) Nouveaux composés
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
RS52142B (sr) 8-[3-amino-piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao farmaceutskih kompozicija
WO2007020261A3 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicament
NO20070089L (no) DPP-IV inhibitorer
NO20062644L (no) DPP-IV inhibitorer
WO2006126082A3 (fr) Pyridine [3,4-b] pyrazinones
WO2007014054A3 (fr) Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2005121078A3 (fr) Composes cyclopentene substitues
WO2009034029A3 (fr) Nouveaux composés
MX2010003849A (es) Antagonistas de cgrp.
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
WO2004014869A3 (fr) Derives de 3,4-dihydropyrimidine-2-one 5,6-fondue, utilise comme inhibiteurs de metalloproteinase matricielle
WO2006034822A8 (fr) Nouveaux amides d'acide thiophenocarboxylique substitues, procede pour les produire et leur utilisation en tant que medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005735460

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2565219

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007508815

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005735460

Country of ref document: EP